Related references
Note: Only part of the references are listed.9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Minimising hypoglycaemia in the real world: the challenge of insulin
Chantal Mathieu
DIABETOLOGIA (2021)
Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis
Erin R. Weeda et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
Harpreet S. Bajaj et al.
DIABETES CARE (2021)
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
Ildiko Lingvay et al.
DIABETES CARE (2021)
The evolution of insulin therapy
Philip Home
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
The current schemes of insulin therapy: Pro and contra
Matthew C. Riddle
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
In Translation: FcRn across the Therapeutic Spectrum
Timothy Qi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans
Thomas B. Kjeldsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Identifying the unmet needs of individuals with Type 2 diabetes: an international web-based survey
Joao Filipe Raposo et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)
CGM-Derived Parameters for Once-Weekly Insulin Icodec vs. Once Daily Insulin Glargine U100 in Insulin Na ve Patients with T2D
Ildiko Lingvay et al.
DIABETES (2021)
Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naive or Experienced Patients with T2D
Robert J. Silver et al.
DIABETES (2021)
Adherence and Persistence in Patients with T2D Initiating Once Weekly vs. Once-Daily Injectable GLP1 RA in US Clinical Practice: STAY Study
Andreas Liebl et al.
DIABETES (2021)
CGM-Based Measurements for Once-Weekly Insulin Icodec vs. Once Daily Insulin Glargine U100 in Insulin Treated Patients with T2D: A Post-hoc Analysis
Harpreet S. Bajaj et al.
DIABETES (2021)
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology
Peter Kurtzhals et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2021)
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
Erica Nishimura et al.
BMJ OPEN DIABETES RESEARCH & CARE (2021)
Second-generation basal insulins to initiate insulin therapy in type 2 diabetes: A need for clinical evidence before incurring increased costs
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2020)
The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Irl B. Hirsch et al.
ENDOCRINE REVIEWS (2020)
Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes
Ulrike Hovelmann et al.
DIABETES (2020)
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Julio Rosenstock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review
Vincent Woo et al.
DIABETES THERAPY (2020)
Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
Tracey Weiss et al.
PATIENT PREFERENCE AND ADHERENCE (2020)
Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes
Bruno Guerci et al.
DIABETES THERAPY (2019)
Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different
Alice Y. Y. Cheng et al.
ADVANCES IN THERAPY (2019)
Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
A. R. Satvik Iyengar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Preclinical Development of an Ultralong-Acting Insulin for Once-Weekly Dosing
Victor G. Howard et al.
DIABETES (2019)
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation
D. R. Owens et al.
DIABETES & METABOLISM (2019)
Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment
Simon Fifer et al.
BMC HEALTH SERVICES RESEARCH (2018)
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Huanbo Tan et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes
Robert Ritzel et al.
DIABETES OBESITY & METABOLISM (2018)
Identification of barriers to insulin therapy and approaches to overcoming them
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2018)
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2018)
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
Tim Heise et al.
DIABETES OBESITY & METABOLISM (2017)
Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
Lei Qin et al.
DIABETES THERAPY (2017)
Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
Lei Qin et al.
DIABETES THERAPY (2017)
LAPSInsulin115: A novel ultra-long-acting basal insulin with a unique action profile
Nina Wronkowitz et al.
DIABETES OBESITY & METABOLISM (2017)
Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes
C. Victor Spain et al.
CLINICAL THERAPEUTICS (2016)
Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance
David R. Owens
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database
Kristina Secnik Boye et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
Ronan Roussel et al.
DIABETES THERAPY (2016)
Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
Ronan Roussel et al.
DIABETES THERAPY (2016)
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
Qing Qiao et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
Tim Heise et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Adherence to insulin treatment in insulin-naive type 2 diabetic patients initiated on different insulin regimens
Dilek Gogas Yavuz et al.
PATIENT PREFERENCE AND ADHERENCE (2015)
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Timo Rath et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2015)
New Insulin Glargine 300 Units.mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units.mL-1
Reinhard H. A. Becker et al.
DIABETES CARE (2015)
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
R. E. Ratner et al.
DIABETES OBESITY & METABOLISM (2013)
Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
Onur Baser et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2012)
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Ib Jonassen et al.
PHARMACEUTICAL RESEARCH (2012)
Patient perspectives on once-weekly medications for diabetes
W. H. Polonsky et al.
DIABETES OBESITY & METABOLISM (2011)
Insulin Preparations with Prolonged Effect
David R. Owens
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK
A. Rubino et al.
DIABETIC MEDICINE (2007)
Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes
L. A. Donnelly et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2007)
Share Paper
